文献速递胸部CT

根据Fleischner学会定义对可切除非小细胞肺癌患者间质性肺异常和间质性肺疾病的自动CT定量:预后意义

Automated CT quantification of interstitial lung abnormality and interstitial lung disease according to the Fleischner Society in patients with resectable lung cancer: prognostic significance.
PubMed 文献 · Eur Radiol · 2023-06-02

本研究回顾性纳入2015年1月至2019年12月间接受肺叶或全肺切除术的非小细胞肺癌患者1524例,使用深度学习自动定量软件分析术前CT,按Fleischner学会定义和多学科讨论分为正常、间质性肺异常(ILA)和间质性肺疾病(ILD)组。ILA组87例(5.7%)、ILD组20例(1.3%),两组无复发生存期和总生存期均较差,且纤维化和非纤维化ILA成分定量均与不良生存相关。

要点

  • 可切除肺癌患者术前CT自动定量可识别ILA(5.7%)和ILD(1.3%),两者均提示无复发生存期和总生存期较差。
  • ILD组预后较ILA组更差:无复发生存期HR 5.26 vs 1.81,总生存期HR 7.20 vs 2.13。
  • 纤维化和非纤维化ILA成分定量均与不良无复发生存期和总生存期相关。

核心结论

  • 基于Fleischner学会定义的ILA自动CT定量可根据疾病分类及纤维化和非纤维化ILA成分定量预测可切除肺癌患者的预后。

研究设计与样本

  • 回顾性纳入2015年1月至2019年12月间接受肺叶或全肺切除术的非小细胞肺癌患者1524例,使用市售深度学习自动定量软件分析术前CT,根据定量结果、Fleischner学会定义和多学科讨论分为正常、ILA和ILD组。

诊断标准与关键数值

  • 1524例患者中正常1417例(93.0%)、ILA 87例(5.7%)、ILD 20例(1.3%);ILA组无复发生存期HR 1.81(95%CI 1.25-2.61,p=.002),ILD组HR 5.26(95%CI 2.99-9.24,p<.001);ILA组总生存期HR 2.13(95%CI 1.27-3.58,p=.004),ILD组HR 7.20(95%CI 3.80-13.62,p<.001);正常和ILA组中纤维化ILA成分与无复发生存期相关HR 1.57(95%CI 1.12-2.21,p=.009)、与总生存期相关HR 1.59(95%CI 1.06-2.37,p=.02),非纤维化ILA成分与无复发生存期相关HR 1.11(95%CI 1.01-1.23,p=.03)、与总生存期相关HR 1.17(95%CI 1.03-1.33,p=.01)。

临床应用与阅片要点

  • 定量CT评估ILA可为肺癌患者术后提供预后信息,有助于考虑对复发进行主动监测,尤其是对定量ILA范围较大的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the prognostic significance of automatically quantified interstitial lung abnormality (ILA) according to the definition by the Fleischner Society in patients with resectable non-small-cell lung cancer (NSCLC).

METHODS: Patients who underwent lobectomy or pneumonectomy for NSCLC between January 2015 and December 2019 were retrospectively included. Preoperative CT scans were analyzed using the commercially available deep-learning-based automated quantification software for ILA. According to quantified results and the definition by the Fleischner Society and multidisciplinary discussion, patients were divided into normal, ILA, and interstitial lung disease (ILD) groups.

RESULTS: Of the 1524 patients, 87 (5.7%) and 20 (1.3%) patients had ILA and ILD, respectively. Both ILA (HR, 1.81; 95% CI: 1.25-2.61; p = .002) and ILD (HR, 5.26; 95% CI: 2.99-9.24; p < .001) groups had poor recurrence-free survival (RFS). Overall survival (OS) decreased (HR 2.13 [95% CI: 1.27-3.58; p = .004] for the ILA group and 7.20 [95% CI: 3.80-13.62, p < .001] for the ILD group) as the disease severity increased. Both quantified fibrotic and non-fibrotic ILA components were associated with poor RFS (HR, 1.57; 95% CI: 1.12-2.21; p = .009; and HR, 1.11; 95% CI: 1.01-1.23; p = .03) and OS (HR, 1.59; 95% CI: 1.06-2.37; p = .02; and HR, 1.17; 95% CI: 1.03-1.33; and p = .01) in normal and ILA groups.

CONCLUSIONS: The automated CT quantification of ILA based on the definition by the Fleischner Society predicts outcomes of patients with resectable lung cancer based on the disease category and quantified fibrotic and non-fibrotic ILA components.

CLINICAL RELEVANCE STATEMENT: Quantitative CT assessment of ILA provides prognostic information for lung cancer patients after surgery, which can help in considering active surveillance for recurrence, especially in those with a larger extent of quantified ILA.

KEY POINTS: • Of the 1524 patients with resectable lung cancer, 1417 (93.0%) patients were categorized as normal, 87 (5.7%) as interstitial lung abnormality (ILA), and 20 (1.3%) as interstitial lung disease (ILD). • Both ILA and ILD groups were associated with poor recurrence-free survival (hazard ratio [HR], 1.81, p = .002; HR, 5.26, p < .001, respectively) and overall survival (HR, 2.13; p = .004; HR, 7.20; p < .001). • Both quantified fibrotic and non-fibrotic ILA components were associated with recurrence-free survival and overall survival in normal and ILA groups.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ahn, Lee, Choi, et al. Automated CT quantification of interstitial lung abnormality and interstitial lung disease according to the Fleischner Society in patients with resectable lung cancer: prognostic significance. Eur Radiol. 2023. PMID: 37266656. doi:10.1007/s00330-023-09783-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。